The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | A next-generation CD33-directed ADC for AML
Next-generation antibody-drug conjugates (ADCs) are demonstrating improved safety and tolerability compared with their predecessors. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Daniel DeAngelo, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses the first-in-human trial of IMGN779 (NCT02674763), a novel monoclonal ADC directed against CD33, for relapsed/refractory acute myeloid leukemia (AML). Dr DeAngelo covers the data collected thus far and plans for the future, including exciting combination strategies.
